Sera Prognostics Inc (SERA) - Total Liabilities
Based on the latest financial reports, Sera Prognostics Inc (SERA) has total liabilities worth $25.94 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Sera Prognostics Inc to assess how effectively this company generates cash.
Sera Prognostics Inc - Total Liabilities Trend (2019–2024)
This chart illustrates how Sera Prognostics Inc's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are Sera Prognostics Inc's assets to evaluate the company's liquid asset resilience ratio.
Sera Prognostics Inc Competitors by Total Liabilities
The table below lists competitors of Sera Prognostics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cosmax Nbt Inc
KQ:222040
|
Korea | ₩248.46 Billion |
|
Tainet Communication System
TWO:4905
|
Taiwan | NT$1.48 Billion |
|
Sentelic Corp
TWO:4945
|
Taiwan | NT$122.99 Million |
|
Fluoguide AS
ST:FLUO
|
Sweden | Skr31.70 Million |
|
COWELL FASHION Co.Ltd
KQ:033290
|
Korea | ₩576.69 Billion |
|
ELUON Corporation
KQ:065440
|
Korea | ₩24.94 Billion |
|
KENERGY
KLSE:0307
|
Malaysia | RM38.05 Million |
|
HEMARAJ INDUSTRIAL PROPERTY AND LEASEHOLD FUND
BK:HPF
|
Thailand | ฿95.60 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Sera Prognostics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see SERA market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.89 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sera Prognostics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sera Prognostics Inc (2019–2024)
The table below shows the annual total liabilities of Sera Prognostics Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $24.77 Million | -2.02% |
| 2023-12-31 | $25.28 Million | +45.42% |
| 2022-12-31 | $17.39 Million | +105.39% |
| 2021-12-31 | $8.46 Million | -28.60% |
| 2020-12-31 | $11.86 Million | -3.63% |
| 2019-12-31 | $12.30 Million | -- |
About Sera Prognostics Inc
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman for the prediction of the expectant mother's risk of delivering spontaneously. It is also developing a pipeline of novel bl… Read more